Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Remogliflozin Etabonate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 known ✓ | P31639 | 20/20 | 1.00 |
| ▸ | SLC5A1 | P13866 | 18/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Remogliflozin Etabonate SCHEMBL16421581 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| Remogliflozin Etabonate SCHEMBL15168697 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| Remogliflozin Etabonate SCHEMBL10081649 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| Remogliflozin Etabonate SCHEMBL18432846 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| Remogliflozin Etabonate SCHEMBL10066609 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| Remogliflozin Etabonate SCHEMBL23072082 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| Remogliflozin Etabonate SCHEMBL17034638 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| SCHEMBL14634764 | 0.98 | SLC5A2 (0.95) | SLC5A2SLC5A1 | |
| SCHEMBL14634761 | 0.98 | SLC5A2 (0.95) | SLC5A2SLC5A1 | |
| SCHEMBL877233 | 0.98 | SLC5A2 (0.95) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727528-A1 | A PHARMACEUTICAL FORMULATION COMPRISING LINAGLIPTIN, METFORMIN AND A SGLT-2 INHIBITOR | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi (TR) | 2026-04-22 | — | — | EP | claimed |
| EP-4719430-A1 | COMBINATION TREATMENT AND/OR PREVENTION OF RENAL DISEASES AND/OR HYPERTENSION IN NON-HUMAN MAMMALS COMPRISING ONE OR MORE SGLT-2 INHIBITORS AND TELMISARTAN | Boehringer Ingelheim Vetmedica GmbH (DE) | 2026-04-08 | — | — | EP | claimed |
| EP-4719429-A1 | COMBINATION TREATMENT AND/OR PREVENTION OF CARDIAC DISEASES IN NON-HUMAN MAMMALS COMPRISING ONE OR MORE SGLT-2 INHIBITORS AND PIMOBENDAN AND/OR TELMISARTAN | Boehringer Ingelheim Vetmedica GmbH (DE) | 2026-04-08 | — | — | EP | claimed |
| US-20260069559-A1 | COMBINATIONS OF RXFP1 MODULATORS AND SGLT2 INHIBITORS | ASTRAZENECA AB (SE) | 2026-03-12 | — | — | US | claimed |
| EP-4271674-B9 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4701626-A1 | AMORPHOUS OBICETRAPIB AND SGLT2 INHIBITOR COMBINATION | NewAmsterdam Pharma B.V. (NL) | 2026-03-04 | — | — | EP | claimed |
| EP-4691554-A2 | GLP-1R MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-02-11 | — | — | EP | claimed |
| US-20260014164-A1 | COMBINATION THERAPY FOR PI3K-ASSOCIATED DISEASE OR DISORDER | UNIV CORNELL (US) | 2026-01-15 | — | — | US | claimed |
| EP-4676494-A1 | SYSTEMS FOR DELIVERY OF LIQUID PHARMACEUTICAL COMPOSITIONS IN PARTICULAR COMPRISING ONE OR MORE SGLT-2 INHIBITOR(S) | Boehringer Ingelheim Vetmedica GmbH (DE) | 2026-01-14 | — | — | EP | claimed |
| US-12497382-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2025-12-16 | — | — | US | claimed |
| US-20090093419-A1 | GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND USE THEREOF IN MEDICINES | KISSEI PHARMACEUTICAL CO. LTD. (JP) | 2009-04-09 | — | — | US | claimed |
| US-7465713-B2 | Glucopyranosyloxypyrazole derivatives and use thereof in medicines | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-12-16 | — | — | US | claimed |
| US-7429568-B2 | Antidiabetic agents; human SGLT2 (sodium ion / glucose cotransporter 2) inhibitors; hyperglycemia, obesity; 3-(6-O-ethoxycarbonyl- beta -D-glucopyranosyloxy)-4-[(4-isopropoxyphenyl)methyl]-1-isopropyl-5-methylpyrazole | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-09-30 | — | — | US | claimed |
| US-7393838-B2 | Glucopyranosyloxypyrazole derivatives and use thereof in medicines | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-07-01 | — | — | US | claimed |
| EP-1912656-A2 | METHODS FOR PREVENTING AND TREATING METABOLIC DISORDERS AND NEW PYRAZOLE-O-GLYCOSIDE DERIVATIVES | Boehringer Ingelheim International GmbH (DE) | 2008-04-23 | — | — | EP | claimed |
| US-20070072813-A1 | Methods for preventing and treating metabolic disorders and new pyrazole-O-glycoside derivatives | AJINOMOTO CO., INC. (JP) | 2007-03-29 | — | — | US | claimed |
| WO-2007014895-A2 | METHODS FOR PREVENTING AND TREATING METABOLIC DISORDERS AND NEW PYRAZOLE-O-GLYCOSIDE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-08 | — | — | WO | claimed |
| US-7084123-B2 | Glucopyranosyloxypyrazole derivatives and use thereof in medicines | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2006-08-01 | — | — | US | claimed |
| US-20040063646-A1 | Glucopyranosyloxypyrazole derivatives and use thereof in medicines | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-01 | — | — | US | claimed |
| EP-1354888-A1 | GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND USE THEREOF IN MEDICINES | Kissei Pharmaceutical Co., Ltd. (JP) | 2003-10-22 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260069559-A1 | COMBINATIONS OF RXFP1 MODULATORS AND SGLT2 INHIBITORS | RXFP1, RXFP2, RXFP4 | SLC5A2 6/4885SLC5A1 5/4885 |
| US-20070072813-A1 | Methods for preventing and treating metabolic disorders and new pyrazole-O-glycoside derivatives | IAPP, G6PC1, GPR119 | SLC5A2 6/4885SLC5A1 4/4885 |
| US-20090093419-A1 | GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND USE THEREOF IN MEDICINES | SLC5A2, SLC5A1, SLC2A4 | SLC5A2 1/4885SLC5A1 2/4885 |
| US-20040063646-A1 | Glucopyranosyloxypyrazole derivatives and use thereof in medicines | SLC5A2, SLC5A1, UGGT1 | SLC5A2 1/4885SLC5A1 2/4885 |
| US-20260014164-A1 | COMBINATION THERAPY FOR PI3K-ASSOCIATED DISEASE OR DISORDER | MTOR, IRS1, IGF1R | SLC5A2 112/4885SLC5A1 81/4885 |
| US-12497382-B2 | GLP-1R modulating compounds | GLP1R, GIPR, GPR119 | SLC5A2 37/4885SLC5A1 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.